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Diseases affecting the immune system, such as inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and 
acute lymphoblastic leukemia (ALL), are pathological conditions affecting the pediatric population and are often associated 
with alterations in the intestinal microbiota, such as a decrease in bacterial diversity. Growing evidence suggests that gut 
microbiota can interfere with chemotherapeutic and immunosuppressant drugs, used in the treatment of these diseases, 
reducing or facilitating drug efficacy. In particular, the effect of intestinal microflora through translocation, immunomodula-
tion, metabolism, enzymatic degradation, and reduction of bacterial diversity seems to be one of the reasons of interindi-
vidual variability in the therapeutic response. Although the extent of the role of intestinal microflora in chemotherapy and 
immunosuppression remains still unresolved, current evidence on bacterial compositional shifts will be taken in considera-
tion together with clinical response to drugs for a better and personalized therapy. This review is focused on the effect of the 
intestinal microbiota on the efficacy of pharmacological therapy of agents used to treat IBD, JIA, and ALL.
Over 35,000 bacterial species are present in the human gut 
microbiota, belonging mainly to the phyla of Firmicutes and 
Bacteroidetes, followed by Proteobacteria and Actinobacteria, 
and to a lesser extent to Fusobacteria, Verrucomicrobia, 
Cyanobacteria, and Spirochetes1,2 (Table 1). They are distrib-
uted along the alimentary tract with an increasing gradient 
of density, depending on pH values, and with a different 
composition, depending on nutrients availability and oxygen 
tension. In the small intestine, besides species belonging to 
Bacteroides (Bacteroidetes) and Clostridiales (Firmicutes), 
which strictly adhere to the mucous epithelium forming 
the resident microflora, Proteobacteria and Lactobacillales 
(Firmicutes) are found in the lumen (transient microflora) due 
to the presence of monosaccharides and disaccharides. In 
the colon, where bacterial population reaches the highest 
concentration (about 1012–1013  CFU/mL), Proteobacteria 
greatly decrease, replaced by anaerobic species able to fer-
ment carbohydrates with production of short chain fatty acids 
(SCFAs), such as acetate, propionate, and butyrate. There are 
evidences that gut microbiota plays a fundamental role in the 
healthy immune status maintenance. In particular, intestinal 
microflora and immune system are constantly shaping each 
other in a mutual aim to flourish and to keep the healthy indi-
vidual in balance.3–5 The healthy state of the immune system 
in adulthood is related to the presence of a diversified micro-
flora, which develops in early childhood thanks to a correct 
colonization sequence by different microorganisms.
The initial colonization of the infant gut takes place during 
delivery and undergoes a lot of modifications during the first 
3 years of life, depending on the diet. It is commonly consid-
ered a healthy microbiota, the one developed by full term, 
vaginally delivered, and breast-fed infants. These babies 
are initially colonized by vagina-associated species, mostly 
Lactobacillus (Firmicutes), Prevotella (Bacteroidetes), and, 
to a lesser extent, Bifidobacterium (Actinobacteria)6–8; then, 
breastfeeding stimulates the proliferation of few species of 
Bifidobacterium (B. breve, B. bifidum, and B. longum), which 
become the most prevalent, thanks to their ability to use, as 
the sole carbon source, some human milk oligosaccharides 
abundant in maternal milk and not degraded by the infant’s 
enzymes.9 The microflora composition remains highly sta-
ble during the feeding period and only after the beginning of 
weaning a diversification is observed: 5 days of breast milk 
cessation are sufficient to reduce the level of Bifidobacterium 
and Lactobacillus and increase that of Bacteroides, Blautia, 
and Ruminococcus10; protein and fiber intake have been 
correlated with an increase of Lachnospiraceae and 
Prevotellaceae, respectively11; species like Faecalibacterium 
prausnitzii and Akkermansia muciniphila, almost absent in the 
infant gut, increase significantly during the next 12 months, and 
since 3-years-old, the microbiota achieves the complex and 
stable composition typical of the adult, consisting for > 80% 
of species belonging to Firmicutes and Bacteroidetes.12
A correct colonization sequence is considered very im-
portant for the development of this healthy microbiota: the 
initial proliferation of a low number of aerotolerant species is 
needed for oxygen consumption, which prepares an advan-
tageous environment for the colonization by a high number of 
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anaerobes, including species able to produce SCFA. Events 
like pre-term birth, caesarean section delivery, and feeding by 
formula-milk, are related to formation of a different, disadvan-
tageous, microflora13: pre-term babies are initially colonized 
mainly by opportunistic pathogens, like Enterococcus and 
species belonging to Enterobacteriaceae7; caesarean sec-
tion results in colonization by environmental microorganisms 
(present on the maternal skin or carried by the hospital staff), 
with a low amount of Actinobacteria and a high amount of 
Firmicutes, mainly Clostridia6,7; in the microbiota of formu-
la-fed babies, high amounts of different potential pathogens, 
like Staphylococcus, Enterobacteriaceae, Enterococcus, 
and Clostridium have been found.14 In all cases, the colo-
nization by Bifidobacteria and Lactobacilli is delayed if not 
seriously impaired, dramatically affecting the subsequent 
colonization by microorganisms that play a fundamental 
role in the maturation and maintenance of the immune sys-
tem. For example, Eubacterium rectale, Eubacterium hallii, 
Faecalibacterium prausnitzii, and Roseburia faecis, all be-
longing to Firmicutes phylum, contribute to the intestinal 
immunoregulation, producing butyrate through bacterial 
fermentation of indigestible dietary components introduced 
by the host in the colon environment.15 Butyrate positively 
influences cell proliferation and differentiation, contributing 
to the stability of the gut epithelial barrier. Moreover, it has 
anti-inflammatory and immunomodulatory properties inhib-
iting the nuclear factor kappa β of macrophages, interfering 
with TNFα, interleukin (IL)-6, and myeloperoxidase activity, 
and inducing regulatory T cell (Treg) differentiation.16,17
Furthermore, commensal bacteria are responsible for 
triggering several pathways involved in the regulation of the 
immune system.3 A general consensus exists that Treg cells 
are key mediators of immune responses, maintaining both 
peripheral and mucosal homeostasis.3,5 Although the pri-
mary site of differentiation is the thymus, the induction of 
Treg cells can occur also in the gastrointestinal tract after 
the production of inducing factors by dendritic cells present-
ing antigens derived from commensal bacteria.3 The most 
significant demonstration that intestinal microflora could 
promote the differentiation of CD4-positivity in Treg cells 
and the consequent modulation of immune response was 
provided by Mazmanian et al.18 This study showed that the 
antigen polysaccharide A of the symbiont Bacteroides fragi-
lis, administered to animals with induced colitis, suppresses 
the production of pro-inflammatory IL-17, stimulating the in-
duction of Treg cells.
Other pathways involving toll-like receptors and NOD-like 
receptors have been found to be responsible for the nor-
mal development of the intestinal mucosal immune system.5 
These receptors are able to recognize microbe-associated 
molecular patterns, such as peptidoglycan components, 
and to trigger, respectively, either the innate intestinal im-
mune response or the assembly of inflammasomes.5
From another point of view, the immune system is able 
both to maintain a symbiotic relationship with commensal 
bacteria and to contain microorganisms with pathogenic 
potential.3 The host reaches a condition of homeostasis 
minimizing the contact between pathogenic microorgan-
isms and the epithelial cell surface through a primary barrier 
consisting of mucus, antimicrobial peptides, and secretion 
of immunoglobulin A.3 These structural and immunological 
components are recognized as the “mucosal firewall.”
The ability of the microbiota to directly affect either posi-
tively or negatively the pharmacological properties of drugs, 
especially if orally administered, by enzymatic modifica-
tion, has been recognized about 50 years back. However, 
in the last 10 years, additional systems through which the 
microbiota can modulate the efficacy and/or the toxicity 
of pharmacological treatments have been described and 
recently outlined in five basic key mechanisms structured 
as the “TIMER framework”19: translocation, immunomod-
ulation, metabolism, enzymatic modification, and reduced 
diversity of the microflora components.
Translocation and immunomodulation
The risk of bacterial translocation through the mucosal 
barrier is strictly connected with mucosal damage and in-
testinal permeability.20 Doxorubicin-induced cytotoxicity 
within the gastrointestinal tract manifests as an increase 
in apoptosis in the stem cell zone of the jejunum and as 
mucosal damage, including a decrease in crypt number 
and villus height. Recently, Rigby et al.21 demonstrated that 
mucosal damage is dependent on enteric bacteria. The 
authors observed that doxorubicin chemotherapy caused 
similar levels of apoptosis in both conventionally raised and 
germ-free (GF) mice’s small intestine but alterations in crypt 
depth and number were observed only in conventionally 
raised mice, suggesting that the presence of enteric bacte-
ria could cause an increase of epithelial barrier permeability 
due to their translocation.21
Gut epithelial barrier alterations are characterized by 
shortening of small intestinal villi, interstitial edema, ep-
ithelial discontinuities, and focal invasion of mononuclear 
cells in lamina propria after therapy with both doxorubi-
cin and cyclophosphamide.22 Several studies on mouse 
models validated the role of the chemotherapeutic agent 
cyclophosphamide in increasing intestinal permeability 
and in the resulting bacterial translocation.20,22 Adherens 
and tight junctions, localized at the apical-lateral and lat-
eral membrane, contribute considerably to the regulation 
of paracellular permeability. According to this, Yang and 
colleagues conducted in vivo intestinal permeability as-
says in male Balb/c mice and investigated the expression 
of tight and adherens junctions’ proteins, like occludin, 
zonula occludens-1, and E-cadherin.20 Treatment with cy-
clophosphamide, especially at high doses, was found to 
induce intestinal permeability by reducing the expression 
of tight and adherens junctions’ proteins in the intestinal 
epithelium. Moreover, Viaud and colleagues’ experiments 
evidenced the disruption of the intestinal barrier and the 
subsequent bacterial translocation, through the detection 
of several gram-positive bacteria belonging to Firmicutes 
phylum, including Lactobacillus johnsonii and Enterococcus 
hirae, into mesenteric lymph nodes and the spleen.22 
Furthermore, these authors highlighted the impact of in-
testinal flora on chemotherapy-elicited anticancer immune 
responses. In particular, gram-positive bacteria detected in 
lymphoid organs were found to be indispensable for gearing 
the conversion of CD4-positive T cells into type 17 T helper 
cells (Th17) and type 1 T helper cells, which contribute to 
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control cancer overgrowth. Furthermore, this specific set of 
gram-positive bacteria is able to stimulate the accumulation 
of specific Th17 within the spleen. Interestingly, the tumor 
growth inhibitory effect of cyclophosphamide decreased 
in GF or antibiotic-treated mice, whereas the efficacy of 
chemotherapy was restored by Th17 cells adoptive trans-
fer. Viaud and colleagues demonstrated through this study 
that gut microbiota enhances the anticancer immune 
response.22
Recently, Sougiannis and colleagues conducted in vivo 
experiments, which highlight that gut microbiota modified 
by fluorouracil has an effect on circulating immune cells.23 
In particular, fecal microbiota of mice without the tumor 
and treated with the antitumoral drug were transplanted in 
control mice. Gene expression analysis on colon tissue of 
transplanted mice evidenced a decreased expression of 
genes connected with macrophages profile, such as mono-
cyte chemoattractant protein 1, IL-10, IL-1β, and epidermal 
growth factor-like module containing mucin-like hormone 
receptor 1, compared with controls. In addition, fewer 
CD68-positive cells were detected in the transplanted mice 
colon tissue by immunohistochemical analysis, indicating 
that the engrafted microbiota, previously modified by fluoro-
uracil chemotherapy, contributes to reduce the macrophage 
population.
Moreover, Bacteroides fragilis (Bacteroidetes) plays 
a role in immunomodulation, facilitating checkpoints of 
T-lymphocyte-associated protein 4 blockage response by 
monoclonal antibodies, such as ipilimumab.24 Comparing 
the therapeutic efficacy in specific pathogen-free and GF 
mice after treatment, Vetizou and colleagues24 evidenced a 
control of tumor progression only in specific pathogen-free 
mice and a reduction of splenic CD4-positive T cell activa-
tion and lymphocytes infiltration in GF or antibiotic-treated 
mice. The anticancer activity and the immune cells function 
reappeared after feeding GF and antibiotic-treated mice 
with Bacteroides fragilis, after immunization with its polysac-
charides or after bacterial-specific T cells adoptive transfer.
Enzymatic drug modification and metabolism
Enzymatic drug modification by the microbiota has been 
studied both in vitro, looking for the drug activity after in-
cubation with bacterial cultures and/or bacteria lysates, 
and in vivo, looking for the effect of co-administration of 
antimicrobials during chemotherapy, leading to the precise 
identification of some drug-modifying enzymes and of the 
reactions they catalyse.
Azoreductases produced by many enteric species, 
mostly belonging to genera Clostridium and Eubacterium 
(Firmicutes), play a fundamental role in the activation of the 
azo-bonded prodrugs of 5-aminosalicylic acid used to treat 
patients with ulcerative colitis and Crohn’s disease, as they 
cleave the azoic bond, releasing the active moiety 5-amin-
osalicylic acid. As these bacteria are most abundant in the 
colon, the therapeutic activity of the drug is mainly triggered 
at this level.25
The involvement of gut microbiota in modulating doxoru-
bicin toxicity at the intestinal level has long been known and 
was mainly ascribed to an increase of epithelial permeability, 
as described above. However, the different effects exerted 
by gut bacteria at different levels of the intestinal tracts re-
mained unexplained: apparently protective for the colonic 
epithelium, damaging for the small intestine.21 The identifi-
cation of some doxorubicin inactivating enzymes produced 
by different bacterial species recently helped to explain this 
difference. Raoultella planticola, a gut isolate belonging to 
the Enterobacteriaceae family (Proteobacteria), inactivates 
doxorubicin by a deglycosylation pathway that needs strictly 
anaerobic conditions typical of the colon; also, Klebsiella 
pneumoniae and Escherichia coli, belonging to the same 
family, degrade doxorubicin if incubated in anaerobic con-
ditions, through a yet undefined molybdopterin-dependent 
pathway. On the contrary, in aerobic conditions, bacterial 
metabolisms degrading the drug by an oxidative phosphor-
ylation pathway, which leads to the production of reactive 
oxygen species toxic for the tissues, have been described. At 
the moment, the latter has been found only in environmental 
species26 and there is no evidence that it is expressed by gut 
microbiota. However, the hypothesis that bacterial degrada-
tion of doxorubicin might be either protective or damaging 
to the mucosal epithelium depending on the aerobic (small 
intestine) or anaerobic (colon) conditions is intriguing.27
In some cases, modification of drugs by the microflora 
metabolism causes the release of secondary metabolites 
that are toxic for the host, leading to the need of reducing 
the doses or even modifying the therapy. This is the case 
of irinotecan, an antineoplastic drug used for the treatment 
of colorectal and pancreatic cancers, which is metabo-
lized by the host hepatic carboxylesterases to its active 
moiety, SN-38, part of which is converted to an inactive 
glucuronide and eliminated by the biliary route. The severe 
diarrhea observed in 30–40% of patients, initially consid-
ered simply the consequence of a drug-induced dysbiosis, 
was recently explained with the production of bacterial 
β-glucuronidases by many species of the microbiota (e.g., 
Bacteroides (Bacteroidetes), Clostridium (Firmicutes), and 
Bifidobacterium (Actinobacteria)), which release active 
SN-38 directly in the gut causing epithelial damage and 
consequently diarrhea. This hypothesis was confirmed by 
the addition to the therapy of specific inhibitors of bacterial 
β-glucuronidases, which significantly reduced the incidence 
of diarrhea with no modification of the microflora composi-
tion in mice.28,29
Besides intestinal biotransformation of drugs by gut bac-
teria, the activity of several nucleoside analogues, widely 
used in cancer therapy, is decreased in some patients due 
to the presence of intratumoral bacteria that produce inacti-
vating enzymes: the thymidine phosphorylase produced by 
Mycoplasma species (Tenericutes), detected in different car-
cinoma tissues (e.g., ovarian, cervical, gastric, and colon), 
degrades 5-fluoro-deoxyuridine, 5-trifluorothymidine, and 
5-halogenated-2’-deoxiuridines, causing therapeutic failure; 
restoration of chemotherapy after co-administration of a 
thymidine phosphorylase inhibitor confirmed the involve-
ment of this enzyme.30 Another example is the cytidine 
deaminase production detected in different species of 
Enterobacteriaceae (Proteobacteria) that were found in pan-
creatic carcinomas, which appeared significantly related to 
gemcitabine (2’,2’-difluorodeoxycitidine) resistance exhib-
ited by some patients during treatment31: in this case, the 
13
www.cts-journal.com
Intestinal Microbiota and Immunosuppresant Drugs
Lucafò et al.
efficacy of the treatment was restored by co-administration 
of an antibiotic.
Finally, a recent study, carried out with a high-through-
put approach, extensively analyzed the drug metabolism by 
the gut microbioma in toto, evaluating 76 different bacterial 
species, belonging to different phyla, able to metabolize 271 
orally administered drugs, and suggesting that direct modifi-
cation of drugs by the microbiota could have a much higher 
impact on chemotherapy than thought so far.32
Reduced diversity
There is a growing consensus that diseases affecting 
the immune cells, such as acute lymphoblastic leukemia 
(ALL), inflammatory bowel disease (IBD), and juvenile 
idiopathic arthritis (JIA), are related to changes in gut mi-
crobiota composition (dysbiosis) occurring as a decrease 
in the bacterial diversity.33–35 Although more studies are 
needed to investigate the role of intestinal microflora in 
the onset and exacerbation of autoimmune diseases, it 
is well known that chemotherapeutic agents can modify 
gut microbiota composition, usually reducing bacterial 
diversity and, therefore, improving pathological condi-
tions of patients.19 Evaluation of the gut microbiota after 
cyclophosphamide treatment evidenced changes in gut 
colonization, especially in the small intestine.20,22 One 
week after cyclophosphamide administration, the mu-
cosal microflora of mice bearing subcutaneous cancers 
showed a reduction of phylum Firmicutes (mainly for gen-
era Clostridium, Roseburia, and Coprococcus, and for the 
family of Lachnospiraceae) and a decrease of Lactobacilli 
and Enterococci.22 Another study on mouse models 
highlighted the reduction in bacterial diversity after intra-
peritoneal administration: cyclophosphamide induced the 
predominance of potentially pathogenic bacteria groups 
belonging to Enterobacteriaceae, Pseudomonadaceae 
(Proteobacteria), and Enterococcaceae (Firmicutes).20 
Sougiannis and colleagues noticed that fluorouracil 
chemotherapy alters gut microbiota richness and even-
ness, as already mentioned.23 The authors showed that 
the chemotherapeutic agent increased the amount of 
Actinobacteria and Verrucomicrobia phyla in mice without 
colorectal cancer, whereas differences in the abundance 
of Firmicutes phylum was found to be more evident in 
treated mice bearing the tumor.
Furthermore, recent studies showed a different gut micro-
biota composition in patients with melanoma who respond 
to antiprogrammed cell death protein 1 immunotherapy. 
Metagenomic analysis of stool samples showed a correlation 
between antiprogrammed cell death protein 1 efficacy and the 
amount of Rumicoccaceae (Firmicutes),36 Bifidobacterium 
longum, and Collinsella aerofaciens (Actinobacteria), 
Enterococcus faecium (Firmicutes),37 and Akkermansia mu-
ciniphila (Verrucomicrobia).38
Zhou et al.39 investigated the role of methotrexate in mod-
ifying gut microbiota composition and found out that the 
immunosuppressive drug dramatically alters the diversity of 
gut microbiota as we shall examine in depth afterward.
Interactions and effects of microbiome represented by 
the TIMER scheme, described above, could also be inter-
preted in a pharmacokinetic (PK) and pharmacodynamic 
(PD) framework. In particular, translocation and immuno-
modulation could be considered PD factors, affecting mainly 
the efficacy and adverse effect of drugs, whereas metab-
olism and enzymatic modification determined by bacteria 
on therapeutics are clearly PK parameters, which may alter 
their bioavailability and metabolite profiles. Reduced diver-
sity may act both as a PD or PK determinant, depending 
on the bacterial strains involved: for instance, if a patho-
genic strain prevails, increased drug-induced infections may 
be observed, whereas, if a strain involved in drug activa-
tion is lacking, bioavailability may be reduced. The study of 
the microbiome would, thus, provide additional information 
beyond traditional PK/PD studies, allowing to predict PK 
patterns before drug administration, providing insights on 
mechanisms of resistance that may not be evident by stan-
dard PD consideration, describing tissue-specific effects 
that may be still relevant for drug response and providing 
innovative targets and mechanisms for drug development.
Hereafter, this review will be focused on the effect of the 
microbiome on the efficacy of pharmacological therapy 
of agents that have immunomodulating and antileukemic 
effects, used in particular to treat IBD, ALL, and JIA, patho-
logical conditions affecting the pediatric population. A better 
understanding of factors affecting susceptibility and ther-
apeutic outcomes in this special population of patients is 
particular important because these diseases are particularly 
severe and may lead to permanent negative outcomes com-
promising life quality also in adulthood or even be fatal. The 
pharmacomicrobiome has received particular attention and 
emerging preliminary evidences are being collected and are 
presented in this review.
ROLE OF MICROBIOTA AND EFFICACY OF 
THERAPEUTICS IN IBD
IBD includes two different pathologies, Crohn’s disease 
and ulcerative colitis, that show common clinical charac-
teristics, such as a chronic immune-mediated inflammation 
at different levels of the digestive tract, and alternation 
between active and inactive phases. Although these dis-
eases can manifest at any age, approximately one-quarter 
of patients are diagnosed in childhood or early adulthood, 
when the disease course and subsequent outcomes can be 
particularly severe.40 No definitive cure for IBD is currently 
available and the treatment is mainly focused on the con-
trol of inflammation, through immunomodulators capable of 
inducing and maintaining remission. The main therapies in-
clude aminosalicylates and glucocorticoids used as first-line 
agents, whereas thiopurines are efficacious for maintaining 
remission; more recently, monoclonal antibodies directed 
toward TNF-α (infliximab and adalimumab), the common 
p40 subunit of IL-12 and IL-23 (ustekinumab) and the inte-
grin (vedolizumab) have been introduced.41,42 The effects of 
all these drugs are characterized by a high interpatient vari-
ability, associated with a significant number of side effects.43
Microbiota and IBD susceptibility
Although IBD etiology remains unresolved, a general 
consensus supports the important role of gut dysbiosis in pro-
moting and determining chronic intestinal inflammation.44–46 
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Hundreds of research papers have described the com-
position of IBD intestinal microbiota and its poor bacterial 
diversity in respect to healthy controls; however, it has not 
yet been clarified whether the gut microbial perturbations 
are a cause or an effect of disease.34,47 The results of these 
studies involving pediatric and adult patients with IBD have 
highlighted a common reduction of several bacterial taxa, 
such as Clostridium groups IV (C. leptum) and XIVa (C. coc-
coides), Roseburia, Faecalibacterium prausnitzii (Firmicutes), 
Bacteroidetes, Sutterella (Proteobacteria), Bifidobacterium 
(Actinobacteria), and an increase of Proteobacteria (in par-
ticular Escherichia coli), Pasteurellaceae, Veillonellaceae, 
Fusobacterium, and Ruminococcus gnavus (Firmicutes).48–50 
Moreover, shifts in microbial composition in patients with 
IBD are implicated in disease severity and progression over 
time and seem to be more pronounced in patients with 
Crohn’s disease than in ulcerative colitis.51,52
Microbiota as IBD therapy response biomarkers
Growing evidence suggests that the efficacy of immu-
nomodulators used to treat pediatric and adult patients 
with IBD is associated with modifications of gut microbi-
ota, as well as by the microbial metabolic activities.53 The 
effect of 5-aminosalicyclic acid on the mucosal microbi-
ota composition of 57 patients with ulcerative colitis54 
has been investigated. In particular, the higher abun-
dance of Proteobacteria, such as Escherichia–Shigella 
and Bacteroidetes, including Bacteroides, Prevotella, and 
Parabacteroides, was reduced after 5-aminosalicylic acid 
treatment. Additionally, the authors observed a paral-
lel change between the decrease in disease activity and 
bacterial alteration (e.g., decreased Escherichia–Shigella) 
after 5-aminosalicylic acid treatment, indicating a relation-
ship between the efficacy of the therapy and the bacterial 
load. Swidsinski and collaborators also described the ef-
fect of 5-aminosalicylic acid on the mucosal flora of 20 
patients with ulcerative colitis or indeterminate colitis: the 
anti-inflammatory agent significantly reduced the concen-
trations and adherence of mucosal bacteria (in particular 
Bacteroides and Enterobacteriaceae) in comparison to the 
untreated patients.55
Mercaptopurine treatment was shown to be correlated 
with a reduction of the microbial richness and diversity in 
seven patients with IBD,51 indicating that the immunomod-
ulator may contribute to dysbiosis in patients. Different 
results were obtained following administration of thiopurines 
in colitis mouse models: the drug caused caecal muco-
sa-associated microbiota alteration mainly manifesting as a 
decrease in Bacteroidetes and an increase in Firmicutes.56
Microbiota analysis of fecal samples derived by 56 pa-
tients with ulcerative colitis responsive or poorly responsive 
to anti-TNF therapy (infliximab and adalimumab) revealed a 
separate profile of gut microbiota before treatment start.57 
In particular, a lower dysbiosis index and higher amount 
of Faecalibacterium prausnitzii (Firmicutes) in respond-
ers compared with nonresponders at baseline was found. 
F.  prausnitzii increased also during induction therapy in 
responders, indicating this species as a biomarker of treat-
ment effectiveness.57 Consistent with several studies, 
F. prausnitzii contributes to the reduction of disease activity 
by producing butyrate, a SCFA, which inhibits the differenti-
ation of Th17 cells and increases Treg cells.58
Recently, Yilmaz and collaborators published a simi-
lar paper focused on the role of microbiota composition 
in two independent long-term IBD cohorts (cohort 1 = 346 
patients; cohort 2  =  156 patients).59 Interestingly, patients 
with Crohn’s disease responsive to infliximab or adali-
mumab therapy showed an increase of Actinobacteria, 
including Bifidobacterium, Eggerthella, and Collinsella, and 
Firmicutes, such as Lachnospira and Roseburia, and re-
duced Phascolarctobacterium (Firmicutes). Most of these 
taxa, in particular Lachnospiraceae and Roseburia, produce 
SCFA metabolites, which have important anti-inflammatory 
properties.
Furthermore, in Crohn’s disease, the abundance of 
Eggerthella, Clostridiales, and Oscillospira (Firmicutes) 
increased in patients with quiescent disease, whereas 
Enterobacteriaceae (among which Klebsiella) were asso-
ciated with a more severe clinical course. No significant 
differences were highlighted comparing patients with ulcer-
ative colitis responding to anti-TNF therapy with patients 
failing to respond to treatment.59
To determine whether the gut microbiome can pre-
dict responses to the anti-integrin monoclonal antibody 
vedolizumab in IBD, Ananthakrishnan et al.60 conducted a 
prospective study enrolling 85 patients at the beginning of 
the therapy (baseline microbiota), and at weeks 14, 30, and 
54 after therapy initiation. Only patients with Crohn’s disease 
achieving remission at week 14 showed a significantly more 
diversified microbiome composition and Roseburia inulini-
vorans and Burkholderiales species were more abundant.60
Similarly, Doherty et al.61 evaluated the differences in 232 
patients’ gut microbiota between patients with anti-TNF 
refractory Crohn’s disease responders and nonresponders 
to ustekinumab, a monoclonal antibody directed against 
the common p40 subunit of IL-12 and IL-23. Patients in 
remission after ustekinumab induction presented a higher 
abundance of Firmicutes, in particular Faecalibacterium, 
Blautia, Clostridium XIVa, Ruminococcaceae, and Roseburia. 
The microbiota diversity of responders increased over the 
22 weeks of the study in comparison to nonresponsive pa-
tients. The most predictive elements at baseline were related 
to a high abundance of Faecalibacterium and low amount of 
Escherichia/Shigella. The differences observed in fecal mi-
crobiota before the start of therapy and its modification due 
to therapeutic effectiveness encourages the potential role 
for the microbiota as a response biomarker.
Microbiota species involved in IBD therapeutics 
metabolism
Drug modifications by gut microbes can lead to their ac-
tivation as known for sulfasalazine, an anti-inflammatory 
drug used in the treatment of IBD.62 Sulfasalazine, the pro-
drug of 5-aminosalicylic acid, can be activated through 
cleavage of the azo bond by bacterial azoreductases. The 
recent paper published by Zimmermann and colleagues 
described in detail the microorganisms capable to metabo-
lize sulfasalazine among 76 different bacterial species that 
represent the major phyla of the human gut microbiome.32 
Interestingly, Bacteroidetes (e.g., Alistipes and Prevotella) 
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and Firmicutes (e.g., Clostridium and Ruminococcus gna-
vus) are the phyla with the higher ability to metabolize 
sulfasalazine, whereas this activity seems to be reduced 
or absent among Proteobacteria (e.g., Salmonella typh-
imurium and Escherichia coli). Considering that most of 
these strains are under-represented or over-represented in 
IBD, a change in effectiveness of sulfasalazine, dependent 
on the patient-specific gut microbiota could be important 
to consider.
Bacterial metabolism of thiopurines was first investigated 
in vitro using the representative gut bacteria Escherichia 
coli (Proteobacteria), Enterococcus faecalis (Firmicutes), 
and Bacteroides thetaiotaomicron (Bacteroidetes).56 
Thioguanine (TG) nucleotides (TGNs), the active products of 
thiopurine metabolism, were detected in the bacterial pel-
lets following incubation of log phase cultures of all three 
bacterial strains with 1 mM TG for 120 minutes. Moreover, 
TGNs were also detected by liquid chromatography-double 
mass spectrometry when fecal slurries derived from mice 
were incubated with 5 or 10 μM TG for 6 hours, demonstrat-
ing that generation of TGN can occur via bacterial activation 
too. The intestinal delivery of the drug and the conversion of 
thiopurines to active compounds by microbiota could sig-
nificantly provide a more rapid therapeutic action avoiding 
unwanted toxicity. Furthermore, microbiota profiles asso-
ciated with side effects in patients treated with thiopurines 
could provide interesting insights on potential targeted 
intervention, comprising treatments useful to modulate mi-
crobiota composition.
Thiopurine S-methyltransferase (TPMT) is an enzyme in-
volved in thiopurine metabolism that reduces the conversion 
of these drugs into active TGNs. An orthologue of human 
TPMT was found and characterized also in bacteria (in par-
ticular Proteobacteria).63 Interestingly, the bacterial enzyme 
similarly catalyzes the S-adenosylmethionine-dependent 
transmethylation of thiopurines and shares 45% similarity 
with the human enzyme; however, no data about the role 
of bacterial TPMT on the efficacy of thiopurines in vitro or in 
vivo have been reported.
ROLE OF MICROBIOTA AND EFFICACY OF 
THERAPEUTICS IN ALL
Microbiota and ALL susceptibility
The interest of microbiota in ALL has been growing in re-
cent years. ALL is an oncohematological disorder due to 
malignant transformation and proliferation of lymphoid 
progenitor cells in the bone marrow, followed by their re-
lease in the peripheral blood stream and impairment of 
the mature immune system.64 Several studies highlighted 
the ALL-induced gastrointestinal dysbiosis possibly due 
to an interaction between the immune system and host 
microbiota, in particular in the gut immunological niche.65 
Rajagopala and collaborators extracted DNA from the 
stool samples of 28 pediatric and adolescent patients 
at diagnosis (before chemotherapy) and 23 matched 
healthy siblings to compare the gastrointestinal microbi-
ota composition by 16S rRNA gene sequencing.66 They 
demonstrated that, in both groups, microbiota profiles 
were dominated by members of the Bacteroidetes (gen-
era Bacteroides and Prevotella) and Firmicutes phyla 
(genus Faecalibacterium), although with changes in the 
mean abundances (lower percentages of Bacteroides, and 
higher percentages of Prevotella, and Faecalibacterium 
in ALL). Major differences between the two groups oc-
curred in the remaining less represented taxa with lower 
diversity in patients: genera Anaerostipes, Coprococcus, 
Roseburia, and Ruminococcus (Firmicutes phylum) had 
relatively lower abundance in the patient group.66 In agree-
ment with Rajagopala’s results, Bai and coworkers67 
also found that the amount of Firmicutes decreased and 
that of Bacteroidetes increased in 10 children with ALL 
compared with 17 healthy controls: Lachnospiraceae, in 
particular Blautia genus, and Erysipelotrichiaceae fami-
lies (Firmicutes) were less abundant in children with ALL; 
Bacteroidales (Bacteroidetes) were more abundant in chil-
dren with ALL and Porphyromonadaceae (Bacteroidetes) 
and Enterococcaceae (Firmicutes) families were effective in 
distinguishing children with ALL from controls.
Patients with ALL have often been treated with antibiot-
ics before diagnosis to treat infections, which are a major 
symptom of the disease. The study of Bai and coworkers67 
demonstrated that antibiotics reduced the microbiota diver-
sity, indeed, the administration of antibiotics for < 1 month in 
healthy children (n = 20) reduced the number of species and 
decreased the diversity of their gastrointestinal microbiota 
compared with those without antibiotics (n = 17). However, 
changes caused by ALL cannot be eliminated or neutralized 
by antibiotics: indeed, with regard to diversity, samples from 
children with ALL always diverged from the controls, regard-
less of antibiotic use.67
Microbiota as ALL chemotherapy response 
biomarkers
ALL polychemotherapeutic treatment is long-lasting (overall 
length ~ 2–3 years) and is organized in an initial remission 
induction phase (~  2  months) followed by consolidation 
(~  2  months) and a long continuation afterward. Hakim 
and coworkers68 analyzed the gastrointestinal microbi-
ota changes over therapy phases in 199 children with ALL 
treated at St. Jude Children’s Research Hospital (Memphis, 
TN) according to the clinical trial Total XVI (NCT00549848). 
Induction treatment began with prednisone, vincristine, 
daunorubicin, PEG-asparaginase, and triple intrathecal 
treatment (methotrexate, cytarabine, and corticosteroids), 
followed by cyclophosphamide, cytarabine, and thiogua-
nine. Consolidation included high doses of methotrexate 
and mercaptopurine plus triple intrathecal therapy every 
other week. Continuation therapy varied week by week 
and comprised two periods of more intensive chemo-
therapy (re-induction I in weeks 7–9 and re-induction II in 
weeks 17–20). Microbiota diversity significantly decreased 
after higher intensive therapeutic phases: indeed, it de-
creased from diagnosis to the end of induction, reverted 
to the baseline level after less-intensive consolidation and 
continuation treatment before re-induction I, and signifi-
cantly decreased again after intensive re-induction II.68 
Compared with baseline, Bacteroidetes, Actinobacteria, 
and Verrucomicrobia phyla, as well as Firmicutes fami-
lies Faecalibacterium and Ruminococcaceae significantly 
decreased in at least one of the postchemotherapy 
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samples. In contrast, other Firmicutes families, including 
Clostridiaceae, Streptococcaceae, Lactobacillaceae, and 
Enterococcaceae significantly increased after chemother-
apy.68 In addition, in the Rajagopala study, the increased 
differences of gut microbial communities were observed 
during the maintenance phase compared with prechemo-
therapy baseline.66
Prior chemotherapy may have a lasting effect on micro-
bial ecosystems, affecting the success of therapy coming 
afterward. Dysbiosis was studied in 20 patients with leuke-
mia, 13 after induction therapy, and 7 after repeat (salvage) 
therapy due to persistent or relapsed disease, measuring 
the similarity of microbiota in longitudinal samples collected 
throughout induction or repeat therapy. Compared with in-
duction samples, bacterial composition of the repeat therapy 
samples showed less similarity to their baseline pretherapy 
samples and a more prominent Enterococcus (Firmicutes) 
outgrowth over time, suggesting that the major microbiota 
instability observed at salvage therapy potentially resulted 
in greater vulnerability of microbiota to enterococcal patho-
genic genera.69
Altogether, the above-mentioned studies on patients are 
descriptive of alterations happening in the gastrointestinal 
microbiota during and following chemotherapy regimens. 
Major interest in the ALL field is to get more detailed infor-
mation on microbial profiles that are associated with clinical 
response. Currently, the predictive value of the minimal resid-
ual disease assessed on bone marrow on clinical outcome is 
very well known, whereas the role of microbiota still needs 
to be well-established. In the ALL field, microbiota could be 
especially useful to predict drug-induced gastrointestinal 
side effects, particularly the development of various infec-
tions and persistent diarrhea. To our knowledge, the only 
study assessing this issue in ALL is the one of Hakim et al.68 
A baseline gut microbiota characterized by Proteobacteria 
phylum and some components of the Lactobacillales fam-
ilies (Firmicutes phylum) was associated with severe side 
effects during chemotherapy. Proteobacteria had been 
correlated to an increased incidence of febrile neutropenia, 
Enterococcaceae (Firmicutes, relative abundance  ≥  30%) 
predicted significantly greater risk of subsequent febrile neu-
tropenia and diarrheal illness, whereas Streptococcaceae 
(Firmicutes) dominance predicted significantly greater risk 
of subsequent diarrheal illness.68
Small animal models have been used to investigate the 
mechanism of gastrointestinal toxicity induced by a single 
antileukemic drug, and the effect on the resident microbi-
ome, as already highlighted for cyclophosphamide.20,22 
Methotrexate is a gold-standard drug during ALL therapy 
and is used throughout all therapeutic phases (i.e., intra-
thecally in induction, at high doses (2–5 g/m2 i.v. infusion) 
during consolidation and at low doses (20  mg/m2 per os) 
in maintenance). Although methotrexate is safely adminis-
tered to most patients, it can cause significant multi-organ 
toxicities, including intestinal toxicity typically accompa-
nied with nausea, bloating, abdominal pain, and diarrhea.70 
Mechanisms by which methotrexate induces intestinal im-
pairment are multiple and include a direct cytotoxic effect 
on intestinal epithelial cells, a dysregulation of the intesti-
nal mononuclear phagocyte system, comprising dendritic 
cells and macrophages, and consequent imbalance in the 
host gut microbiota. Mice intraperitoneally injected with 
1  mg/kg of methotrexate for 14  days developed mucosal 
damage accompanied by inflammatory cells’ infiltration and 
significant changes in macrophages in the colon. By ana-
lyzing gut microbiota by high throughput pyrosequencing 
of 16S rRNA gene amplicons over the treatment period, 
a gradually reduced diversity of the total microbiota was 
observed: Bacteroidales order (Bacteroidetes) were dra-
matically reduced in the feces, whereas Lachnospiraceae 
family (Firmicutes) underwent a sharp increase after metho-
trexate treatment in a time-dependent manner.39 In another 
rat mucositis model, methotrexate infusion induced also 
an overall decrease (705-fold) in most bacteria compared 
with controls. Reduced bacterial presence was related 
with diarrhea and a reduced villus length. After 4  days of 
treatment, there was an absolute and relative decrease of 
commensal protective intestinal anaerobes (13-fold and 
–58%, respectively), including Ruminococci species, and of 
oxygen-tolerant Firmicutes streptococci (296-fold and –1%, 
respectively).71 However, in contrast to the previous study, a 
relative increase of enteropathogenic anaerobic Bacteroides 
genera compared with controls (+49%) was observed.
Microbiota species involved in ALL chemotherapeutic 
metabolisms
Being the oncologic approach polychemotherapeutic, it is 
not easy to understand which drug is most altered by the 
microbiota. A recent already mentioned outstanding study 
measured the ability of 76 human gut bacteria to metabolize 
271 orally administered drugs (including agents used in an-
tileukemic therapy, such as the corticosteroids prednisone 
and dexamethasone, cyclophosphamide, and the tyrosine 
kinase inhibitors, imatinib and dasatinib), and combined 
high-throughput genetic analyses with mass spectrome-
try to systematically identify microbial gene products that 
metabolize drugs.32 In this screen, dexamethasone was 
metabolized by Clostridium scindens (Firmicutes) in ax-
enic bacterial cultures and was metabolized (side chain 
cleavage) in the intestine, particularly in the cecum, in mice 
mono-colonized with Clostridium scindens compared with 
GF mice. Notably, anaerobic incubation of dexamethasone 
with fecal cultures from 28 healthy human donors showed 
substantial interpersonal variation in metabolite production, 
suggesting that other bacterial taxa may also metabolize 
dexamethasone. A similar pattern was reported also for 
prednisone. Several Bacteroides species (Bacteroidetes), 
also significantly reduced (> 20%) corticosteroids: in par-
ticular, Bacteroides dorei acts on both dexamethasone 
and prednisone. Cyclophosphamide is metabolized mainly 
by Firmicutes taxa, although the main metabolizer was 
Alistipes indistinctus (Bacteroidetes). Among tyrosine ki-
nase inhibitors, imatinib was decreased after incubation 
with several Bacteroides species (Parabacteroides john-
sonii, Bacteroides eggerthii, Bacteroides vulgatus, 
and Bacteroides stercoris), whereas dasatinib was af-
fected by Clostridium species (including Clostridium 
bolteae, phylum Firmicutes) and also by Bifidobacterium 
ruminatum (Actinobacteria phylum) and Bacteroides fragilis 
(Bacteroidetes).
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ROLE OF MICROBIOTA AND EFFICACY OF 
THERAPEUTICS IN JIA
Rheumatological diseases, such as rheumatoid arthritis or 
JIA, are a clinically heterogeneous group of conditions char-
acterized by chronic arthritis, synovial inflammation, and 
erosion of bone and cartilage, and significant associations 
with variations in the microbiota have been described. In 
particular, for spondyloarthritis, a rheumatological disease 
that affects both the joints and entheses, gut inflammation 
is present,72 which may be associated with abnormalities in 
the composition of the gastrointestinal microbiota.
Microbiota and JIA susceptibility
Specific bacterial species potentially associated with JIA 
have been identified. Among major environmental factors 
that can impact the composition of microbiota, deliv-
ery mode and early exposure to antibiotics have been 
demonstrated to be relevant for the incidence of these pa-
thologies. A population and national register-based cohort 
study performed in Denmark indicated that, among all chil-
dren born in the country from January 1997 to December 
2012, those delivered by cesarean section were at in-
creased risk of disease associated with immune function. 
In particular, elective cesarean section was associated with 
an increased risk of JIA.73 For antibiotic use, in a nested 
case-control study in a large pediatric population database 
from the United Kingdom, antibiotic administration was as-
sociated with newly diagnosed JIA, with a dose-dependent 
and time-dependent effect.74 Both these associations may 
be mediated through alterations in the microbiota.
An analysis of the composition of the fecal microbiota of 
30 children with new-onset JIA compared with 27 healthy 
controls by 16S region-based sequencing profiling, identi-
fied a lower proportion of bacteria belonging to the phylum 
Firmicutes in children with JIA compared with controls, 
whereas bacteria belonging to Bacteroidetes were signifi-
cantly more abundant in JIA than in control samples.75 These 
results are in agreement with previous analyses performed 
in other rheumatic diseases, such as spondyloarthritis.76,77 
This study also described that phyla Actinobacteria and 
Fusobacteria were present only in patients with JIA, whereas 
phylum Lentisphaerae was present only in controls. No differ-
ences between patients with JIA and controls in the diversity 
indexes was found in this study.75 Another study considered 
children with a JIA subtype, enthesitis-related arthritis (JIA-
ERA). This study enrolled 25 children with JIA-ERA and 13 
controls. Patients with JIA-ERA had less Faecalibacterium 
prausnitzii, a bacterial species that is considered to have 
anti-inflammatory effects through production of SCFAs, 
such as butyrate.78 Moreover, increased abundance of 
Bacteroides and of the Verrucomicrobia Akkermansia mu-
ciniphila was evident.79
Metabolomic profiling of fecal samples of children with 
JIA-ERA was performed by nano-liquid chromatogra-
phy-mass spectroscopy, combined with sequencing of the 
16S ribosomal DNA on the same stool specimens. These 
analyses revealed an under-representation of multiple met-
abolic pathways, including the tryptophan metabolism 
pathway. Significantly fewer microbial genes associated 
with metabolic processes in the patients compared with the 
controls were observed, indicating diminished metabolic di-
versity as a potential feature of JIA-ERA.80
A study in an Italian cohort of 29 patients with JIA (19 
with JIA-ERA and 10 with JIA-non ERA) in comparison to 
29 healthy controls, identified differences in various bacterial 
families belonging to the Firmicutes phyla.81 In particular, in 
comparison to healthy subjects, Ruminococcaceae resulted 
as increased in patients with JIA, Veillonellaceae in JIA-non 
ERA, whereas Clostridiaceae and Peptostreptococcaceae 
were decreased in JIA-ERA. This study, therefore, illus-
trates clearly a more complex pattern of association of the 
Firmicutes phylum abundance, than a more general pattern 
of reduction described by previous studies in JIA75 and 
other rheumatic or immune-mediated diseases.82 Authors 
underline in particular that the enrichment of gram-positive 
Clostridium cluster XIVb in patients with JIA-ERA suggests 
a causal relation with inflammation. Indeed, previous studies 
have indicated that cell wall peptidoglycans of Clostridium 
and other anaerobic gram-positive species can induce ar-
ticular damage if the peptidoglycan has lysine as the third 
amino acid of the stem peptide.83 Also, this study identi-
fied a reduction in Faecalibacterium, considered to be an 
anti-inflammatory microorganism, in JIA-non ERA.84 A study 
in Asian patients considered 33 patients with JIA-ERA and 
14 age matched controls. All patients had active arthritis 
and were receiving exclusively nonsteroidal anti-inflamma-
tory drug (NSAID) therapy (no immunosuppressive drugs, 
disease modifying anti-rheumatic drugs, or biologicals). Gut 
microbiota showed dysbiosis in patients with JIA-ERA, which 
presented a wider dispersion than controls. Bacteroidaceae 
(Bacteroidetes) and Enterobacteriaceae (Proteobacteria) 
were more abundant and Prevotellaceae (Bacteroidetes) 
were less abundant than in controls. In addition, the genera 
Bacteroides (Bacteroidetes), Enterococcus (Firmicutes), and 
Klebsiella (Proteobacteria) were over-represented and the 
genus Prevotella (Bacterioidetes) was under-represented in 
patients with JIA-ERA.85 This study also evaluated, in eight 
patients, the effect of 12 weeks of probiotic therapy (VSL#3; 
Sun Pharmaceuticals, Mumbai, India) twice daily orally, with 
each capsule containing around 100 billion bacterial cells 
belonging to eight species, namely Streptococcus ther-
mophilus (Firmicutes), Bifidobacterium breve, B.  longum, 
B.  infantis (Actinobacteria); Lactobacillus acidophilus, 
L.  plantarum, L.  paracasei, and L.  delbrueckii (Firmicutes) 
as part of a clinical trial. However, no significant difference 
was noticed between the fecal specimens collected before 
and after probiotic intake, considering diversity and abun-
dances of various bacterial taxa at all levels. The authors 
discussed this negative result as in line with comprehensive 
analyses that reveal a lack of evidence for an impact of pro-
biotics on fecal microbiota composition in healthy adults86 
and children.87
A recent study attempted to clarify the association of 
alteration of Bacteroides and reduction in Firmicutes, in 
particular of Faecalibacterium prausnitzii in a cohort of adult 
and pediatric patients with spondyloarthritis and JIA-ERA. 
This cohort was composed of 11 adult and 30 pediatric pa-
tients, compared with, respectively, 10 and 19 age-matched 
controls. Recent exposure to systemic antibiotics was an 
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exclusion criterion. Adult patients could be treated with im-
munomodulators (classic disease modifying anti-rheumatic 
drugs or biologics), whereas all pediatric patients were 
treatment naïve at the moment of enrollment. Pairwise com-
parisons at most of the phylogenetic levels failed to identify 
any groupwise differences. The only exception was that pa-
tients with JIA-ERA demonstrated decreased abundance 
of the Actinobacteria phylum as compared with controls. 
A candidate analysis focused on Faecalibacterium praus-
nitzii and Bacteroides fragilis (Bacteroidetes) indicated a 
decreased abundance of the anti-inflammatory F. prausnitzii 
A2-165 strain and an increased abundance of the neu-
tral F.  prausnitzii L2/6 strain. However, the abundance of 
F. prausnitzii as a whole was nominally higher in the patients, 
in contrast to previous results from the same group already 
discussed above.79 Shotgun metagenomics sequencing of 
the fecal DNA in the pediatric subjects confirmed diminished 
coverage of the anti-inflammatory butyrate pathway. Similar 
trends were observed in adults with longstanding spondy-
loarthritis. In contrast, the fecal abundance of Bacteroides 
fragilis (Bacteroidetes) was increased in patients with JIA-
ERA, whereas resulted as diminished in adult subjects 
compared with controls. This difference may be related to a 
role of Bacteroides fragilis in the development of the immune 
system,88 but may be also affected by the fact that, in this 
study, > 80% of adult patients were under immunomodulat-
ing therapy.89
A recent large multicentric study, enrolling 78 Italian and 
21 Dutch treatment-naive patients with JIA compared with 
107 geographically matched samples from healthy children, 
also did not confirm in patients with JIA a protective effect 
of Faecalibacterium prausnitzii, that actually resulted as 
increased, together with Erysipelotrichaceae (Firmicutes); 
Allobaculum (Firmicutes) was instead reduced. Forty-four 
follow-up samples from patients with inactive disease and 
25 follow-up samples from patients with persistent activity 
were also analyzed. Microbiota richness, in terms of rare 
species, was reduced in patients with JIA compared with 
healthy controls, at baseline, during inactive disease, and 
during persistent disease activity, especially in Italian sub-
jects. However, when comparing baseline samples with 
paired inactive disease samples, no differences in relative 
abundance were found. This finding may indicate that the 
gut microbiota profile is specific to the individuals with JIA, 
rather than the disease activity status.90
Microbiota as JIA therapy response biomarkers
Regarding the effect of pharmacological therapies on gut 
microbiota of patients with JIA, one of the first studies to 
describe potentially significant associations considered 
a group of patients with JIA-ERA treated with NSAIDs, 
alone or associated with sulfasalazine/methotrexate/bio-
logics in different combinations, and a group of patients 
with JIA-non ERA, mainly treated with biologic drugs, such 
as etanercept and abatacept. Despite the low number of 
patients stratified by pharmacological treatment, authors 
observed enrichment in Collinsella (Actinobacteria), as-
sociated with exacerbation of joint disease, in patients 
with JIA-ERA treated with combined NSAIDs and sulfas-
alazine therapy. The abundance of Collinsella correlated 
strongly with inflammation markers as well as production 
of the proinflammatory cytokine IL-17A also in adult pa-
tients with rheumatoid arthritis and a role for Collinsella 
in altering gut permeability and disease severity was 
confirmed in experimental arthritis.91 Among the patients 
enrolled, 19% of patients with JIA-ERA and 41% of pa-
tients with JIA-non ERA presented clinically active disease: 
Sutterella (Proteobacteria) was increased in samples col-
lected during active disease, whereas Clostridium cluster 
IV and XVIII (Firmicutes), Parasutterella (Proteobacteria), 
and Odoribacter (Bacteroidetes) were more abundant in 
samples collected from patients in remission. Prediction 
analysis of metabolic functions indicated that JIA-ERA 
metagenome presented enrichment in bacterial functions 
associated with cell motility and chemotaxis, suggesting 
selection of potential virulence traits.81
A recent study attempted to develop algorithms to 
predict inactive disease according to Wallace criteria at 
6-month intervals in the first 2 years of JIA. Potential pre-
dictors were baseline clinical variables, joint status, gut 
microbiota composition, and a panel of inflammation- 
related compounds in blood plasma. The study consid-
ered 152 treatment naïve patients with JIA, who could be 
treated with standard therapies, categorized in the study 
as intra-articular joint injections with or without NSAIDs, 
methotrexate with or without oral steroids, and biologi-
cal agents. Inactive disease could not be predicted with 
satisfactory accuracy in the whole cohort, likely due to dis-
ease heterogeneity. However, a gut microbiota-associated 
predictor in a subgroup of patients was identified: in par-
ticular, inactive disease was predicted by a lower relative 
abundance of Mogibacteriaceae (Firmicutes) for patients 
with oligoarthritis.92 Authors discuss that nothing is known 
about Mogibacteriaceae in the context of autoimmune dis-
eases, whereas this bacterium was less present in obese 
Japanese subjects, in comparison to lean subjects.93
In 18 French adult patients with spondyloarthritis, modi-
fications of the microbiota composition were observed after 
3 months of anti-TNF treatment (15 patients received etaner-
cept, 2 received adalimumab, and 1 received infliximab), 
but no specific taxon was modified, whatever the clinical re-
sponse. Authors performed an analysis to identify predictors 
of anti-TNF treatment after 3 months of therapy, selecting two 
subgroups of patients, five with good response (change in dis-
ease activity score > 2), and eight with limited efficacy (change 
in disease activity score < 1). Before anti-TNF administration, a 
higher proportion of Burkholderiales (Proteobacteria) in future 
responder patients was identified by this study. This suggests 
an interaction between anti-TNF treatment and intestinal mi-
crobiota even if further studies are needed.94
A recent study, also performed in adult patients with 
rheumatoid arthritis, enrolled 42 patients divided according 
to current therapy: 11 patients were naïve to immunosup-
pressants, 11 patients were receiving methotrexate, 10 
patients were receiving the anti-TNF agent etanercept, and 
10 patients were receiving etancercept plus methotrexate. 
Ten healthy subjects were used as controls. The relative 
abundance of the microbial phyla was almost unchanged 
between patients and controls. When compared with naïve 
patients, significant changes were recorded in patients 
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treated with etanercept: phylum Cyanobacteria significantly 
increased, in particular, in the Nostocophycideae class. In 
the group of patients treated with methotrexate, a decrease 
in the amount of Enterobacteriales (Proteobacteria) was 
described, whereas no significant variations were seen in 
patients treated with etanercept and methotrexate.95
Microbiota species involved in JIA therapeutics 
metabolism
Studies on the effect of drug therapy on microbiota are still 
limited, especially in children. Methotrexate is a very im-
portant medication also for the treatment of JIA and it is 
known that intestinal microbiota in rodent models can mod-
ify this drug, but the implication of this finding in patients 
still needs to be explored.96
DISCUSSION AND CONCLUSIONS
The microbiota is clearly altered in diseases involving im-
mune system cells, such as IBD, ALL, and JIA, even if 
generalization of the findings described are still limited by 
the small sample sizes and by the influence of confounding 
environmental factors, such as patients’ age or geographic 
areas of the studies. Moreover, besides the presence 
of reproducible associations, such as alterations of the 
Faecalibacterium/Bacteroidetes ratio, demonstration of the 
causality between differences observed and diseases still 
needs to be provided. This is particularly true also for the 
effects of microbiota on the activity of immunomodulatory 
and antileukemic agents (Figure 1). The needs of research 
in this field are larger studies in pediatric patient popula-
tions to identify bacterial strains associated with disease 
subtype and drug responses, with better control of envi-
ronmental factors, such as diet, hygiene, and geographic 
location.
The overall utility of characterizing microbial composition 
in dosing drugs still has to be determined. For some chemo-
therapeutics, such as irinotecan, a clear contribution of the 
microbiota in determining drug-induced gastrointestinal tox-
icity has been proved and the use of inhibitors of bacterial 
glucuronidases, which release in the intestine the cytotoxic 
form, may be important to reduce adverse effects. Emerging 
evidence seems to indicate that, in patients with IBD, a 
higher abundance of Firmicutes may be important for the 
efficacy of biologic agents, such as anti-TNF drugs, whereas 
in ALL and JIA more research is needed before drawing spe-
cific patterns of association between bacterial strains and 
therapeutic response.
Current evidence seems to indicate that bacterial com-
position before or during treatment may affect drug effects 
and an application of the microbiome analysis could be the 
identification of bacterial strain present, putatively predictive 
both in terms of efficacy or adverse effects, and its modi-
fication by interventions, such as antibiotic administration. 
Because infections could be a consequence of all immu-
nosuppressive therapies, microbioma profiling could be 
proposed as an infection risk stratification tool and used 
to propose personalized treatment approaches. In this re-
gard, the modification of microbiome composition seems 
to be promising in applying the pharmacomicrobiome to 
Figure 1 Representative scheme of possible interactions between drugs and gut-associated microbioma. ALL, acute lymphoblastic 
leukemia; IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis.
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improve therapeutic outcomes. Besides the use of antibiot-
ics, additional customized innovative interventions could be 
developed, such as probiotics, fecal microbiota transplant, 
and modified diet. The efficacy of these strategies to mod-
ify the microbioma in the clinical setting still needs to be 
fully demonstrated. In ALL, the hypothesis that the relative 
abundance of species at diagnosis could be predictive of 
chemotherapy-induced toxicities, given their severity, is par-
ticularly intriguing, and deserves further studies.
Although different models demonstrate the role of spe-
cific bacteria on the biotransformation and modulation of 
the effects of these drugs, evidence of their role in inter-
individual variability in patients is still lacking. However, to 
really understand the relevance of microbiota composition 
for the interindividual variability in drug responses mecha-
nistic studies using innovative experimental approaches are 
also important. Combination of high-throughput genetics 
with mass spectrometry to systematically identify drug- 
metabolizing microbial gene products could be relevant. As 
already mentioned in this review, a recent study applied this 
approach, validating 30 microbiome-encoded enzymes that 
collectively convert 20 drugs to 59 candidate metabolites 
and providing a mechanistic understanding of microbiome 
drug biotransformation.32 Moreover, a paradigmatic study 
separating host and microbiome contributions to drug PKs 
and toxicity has been published combining gut commensal 
genetics in gnotobiotic mice carrying no microbiota, genet-
ically manipulated gut commensals, or a complex microbial 
community, to measure drug metabolism in various tissues.97
These mechanistic studies will be particularly important 
for drug development: knowing the interaction between 
the microbiota and approved drugs could favor the devel-
opment of computational models for the identification of 
new molecules, such as inhibitors or prodrugs activated by 
specific bacterial enzymes, or optimization of existing drugs 
and formulations. In this regard, bacteria may provide tar-
gets that could be pharmacologically modified to improve 
therapeutic outcomes. Agents addressing bacterial targets 
not present in human cells may have limited side effects. 
Moreover, particularly important, as already mentioned, will 
be studies to evaluate innovative pharmacological strategies 
to modify the microbiota. Reducing specific bacterial strains 
related to therapeutic efficacy may indeed be a promising 
approach.
The research on the interactions between drug effects and 
the microbioma presents several challenges: from an in vitro 
experimental point of view, a feasible approach is to study 
the biotransformation and testing candidate strains on spe-
cific drugs; however, bacterial communities are heterogenous, 
presenting several strains interacting in complex patterns. 
Therefore, innovative microbiological tests should be devel-
oped to evaluate the effects of microbial communities, besides 
individual strains. The complexity of microbiota, in terms of 
changes occurring between several locations in the body, 
also at the intestinal level, constitutes an additional challenge. 
Thus, experimental design needs to be accurate in order to 
collect the most informative samples from patients. Finally, the 
great amount of data generated by microbiota metagenomic 
analysis represents an issue common to all -omic approaches. 
In conclusion, there are several implications of microbial 
alterations for the pharmacological therapy mentioned in this 
review that need further exploration. In particular, it remains 
to be demonstrated whether microbial alteration can explain 
the inter/intra-individual variability or drug levels or responses 
across demographics or comorbidities. Moreover, the impor-
tance of the contribution of the microbiota on standard PK/PD 
factors, like liver/kidney clearance or conjugation, also remains 
to be investigated.
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